Cyclodextrins in transdermal and rectal delivery

Advanced Drug Delivery Reviews

Volumn 36, Issue 1, 1999, Pages 81-99

  Matsuda, Hajime ^a   Arima, Hidetoshi ^b  

^a Fuji   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Complexation; Cyclodextrin; Drug absorption; Drug delivery; Drug release; Local irritation; Permeability; Rectum; Skin; Stability constant

Indexed keywords

COMPLEXATION; DERIVATIVES; DRUG INFUSION; DRUG PRODUCTS; MECHANICAL PERMEABILITY; SKIN;

CYCLODEXTRINS; TRANSDERMAL DRUG DELIVERY;

POLYSACCHARIDES;

8 [3 (4 DIETHYLCARBAMOYL 1 PIPERAZINYL)PROPYL] 1,3,7 TRIMETHYLXANTHINE; BECLOMETASONE DIPROPIONATE; BERMOPROFEN; BETAMETHASONE; CARMOFUR; CEFMETAZOLE; CHLORAMPHENICOL; CHLORPROMAZINE; CIPROFLOXACIN; COSMETIC; CYCLODEXTRIN DERIVATIVE; DIAZEPAM BINDING INHIBITOR; ESTRADIOL; ETRETIN; FELBINAC; FELBINAC ETHYL ESTER; FLURBIPROFEN; FRAGRANCE; GLYCERYL TRINITRATE; GRANULOCYTE COLONY STIMULATING FACTOR; INDOMETACIN; INSULIN; LIAROZOLE; MENADIONE; MICONAZOLE; MORPHINE; NAPROXEN; NORFLOXACIN; PHENOBARBITAL; PIRIBEDIL; PIROXICAM; PREDNISOLONE; PRESERVATIVE; PROSTAGLANDIN E1; RETINOIC ACID; SULFANILIC ACID; TIXOCORTOL 17 BUTYRATE 21 PROPIONATE; TOLNAFTATE; UNCLASSIFIED DRUG;

COMPLEX FORMATION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG STABILITY; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; REVIEW; SUPPOSITORY; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0033106031     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(98)00056-8     Document Type: Review

References (81)

1. K. Uekama, M. Otagiri, Cyclodextrins in drug carrier systems. CRC Crit. Rev. Ther. Drug Carrier Syst. 3 (1987) 1-40.
2. T. Irie, K. Uekama, Pharmaceutical applications of cyclodextrins. 3. Toxicological issues and safety evaluation, J. Pharm. Sci. 86 (1997) 147-162.
3. F. Glomot, L. Benkerrour, D. Duchêne, M.-C. Poelman, Improvement in availability and stability of a dermacorticoid by inclusion in β-cyclodextrin, Int. J. Pharm. 46 (1988) 49-55.
4. 1 through hairless mouse skin: combined use of carboxymethyl-ethyl-β-cyclodextrin and penetration enhancers, J. Pharm. Pharmacol. 44 (1992) 119-121.
5. H. Adachi, T. Irie, F. Hirayama, K. Uekama, Stabilization of prostaglandin E1 in fatty alcohol propylene glycol ointment by acidic cyclodextrin derivatives, O-carboxymethyl-O-ethyl-β-cyclodextrin, Chem. Pharm. Bull. 40 (1992) 1586-1591.
6. 1 in hairless mice, Eur. J. Pharm. Sci. 1 (1993) 117-123.
7. H. Arima, H. Adachi, T. Irie, K. Uekama, J. Pitha, Enhancement of the antiinflammatory effect of ethyl 4-biphenyl acetate in ointment by β-cyclodextrin derivatives: Increased absorption and localized activation of the prodrug in rats, Pharm. Res. 7 (1990) 1152-1156.
8. H. Arima, T. Miyaji, T. Irie, F. Hirayama, K. Uekama, Enhancing effect of hydroxypropyl-β-cyclodextrin on cutaneous penetration and activation of ethyl 4-biphenylyl acetate in hairless mouse skin, Eur. J. Pharm. Sci. 6 (1998) 53-59.
9. S. Tenjarla, P. Puranajoti, R. Kasina, T. Mandai, Preparation, characterization, and evaluation of miconazole-cyclodextrin complexes for improved oral and topical delivery, J. Pharm. Sci. 87 (1998) 425-429.
10. I. Orienti, V. Zecchi, V. Bertasi, A. Fini, Release of ketoprofen from dermal bases in the presence of cyclodextrins:effect of the affinity constant determined in semisolid vehicles, Arch. Pharm. 324 (1991) 943-947.
11. A.A.A. Rahman, S.H. Khidr, S.M. Ahmed, A.E. Aboutaleb, Evaluation of chloramphenicol-β-cyclodextrin inclusion complex, Eur. J. Pharm. Biopharm. 37 (1991) 34-37.
12. N. Udupa, L. Bhat, Evaluation of few ciprofloxacin (CIP) and norfloxacin (NOR) formulations, Drug. Dev. Ind. Pharm. 18 (1992) 2197-2205.
13. M. Otagiri, T. Fujinaga, A. Sakai, K. Uekama, Effects of β-and γ-cyclodextrins on release of betamethasone from ointment bases, Chem. Pharm. Bull. 32 (1984) 2401-2405.
14. K. Uekama, M. Otagiri, A. Sakai, T. Irie, N. Matsuo, Y. Matsuoka, Improvement in the percutaneous absorption of beclomethasone dipropionate by γ-cyclodextrin complexation, J. Pharm. Pharmacol. 37 (1985) 532-535.
15. K. Uekama, K. Arimori, A. Sakai, K. Masaki, T. Irie, M. Otagiri, Improvement in percutaneous absorption of prednisolone by β- and γ-cyclodextrin complexations, Chem. Pharm. Bull. 35 (1987) 2910-2913.
16. K. Uekama, K. Masaki, K. Arimori, T. Irie, F. Hirayama, Effects of β- and dimethyl-β-cyclodextrins on release and percutaneous absorption behaviors of prednisolone from some ointment bases, Yakugaku Zasshi 107 (1987) 449-456.
17. H. Arima, H. Adachi, T. Irie, K. Uekama, Improved drug delivery through the skin by hydrophilic β-cyclodextrins. Enhancement of anti-inflammatory effect of 4-biphenylylacetic acid in rats, Drug Invest. 2 (1990) 155-161.
18. H. Arima, T. Miyaji, T. Irie, F. Hirayama, K. Uekama, Possible enhancing mechanism of the cutaneous permeation of 4-biphenylylacetic acid by β-cyclodextrin derivatives in hydrophilic ointment, Chem. Pharm. Bull. 44 (1996) 582-586.
19. U.V. Singh, S. Pandey, N. Udupa, Drug carriers for transdermal preparations of flurbiprofen, Drug Dev. Ind. Pharm. 20 (1994) 1811-1820.
20. R.D. Narashima, N. Udupa, Formulation and evaluation of oral and transdermal preparations of flurbiprofen and piroxicam incorporated with different carriers, Drug. Dev. Ind. Pharm. 19 (1993) 843-852.
21. S.Z. Lin, D. Wouessidjewe, M.C. Poelman, D. Duchêne, In-vivo evaluation of indomethacin/cyclodextrin complexes Gastrointestinal tolerance and dermal anti-inflammatory activity, Int. J. Pharm. 106 (1994) 63-67.
22. T. Higuchi, Physical chemical analysis of percutaneous absorption process from creams and ointments, J. Soc. Cosmet. Chem. 11 (1960) 85-97.
23. T. Loftsson, H. Friôriksdóttir, G. Ingvarsdóttir, B. Jónsdóttir, A.M. Sigurôaraóttir, The influence of 2-hydroxypropyl-β-cyclodextrin on diffusion rates and transdermal delivery of hydrocortisone, Drug Dev. Ind. Pharm. 20 (1994) 1699-1708.
24. U. Vollmer, B.W. Müller, J. Mesens, B. Wilffert, T. Peters, In-vivo skin pharmacokinetics of liarozole: Percutaneous absorption studies with different formulations of cyclodextrin derivatives in rats, Int. J. Pharm. 99 (1993) 51-58.
25. U. Vollmer, B.W. Mülller, J. Peeters, J. Mesens, B. Wilffert, T. Peters, A study of the percutaneous absorption-enhancing effects of cyclodextrin derivatives in rats, J. Pharm. Pharmacol. 46 (1994) 19-22.
26. A.M. Sigurôardóttir, T. Loftsson, The effect of polyvinylpyrrolidone on cyclodextrin complexation of hydrocortisone and its diffusion through hairless mouse skin, Int. J. Pharm. 126 (1995) 73-78.
27. T. Loftsson, A.M. Sigurôardóttir, The effect of polyvinylpyrrolidone and hydroxypropyl methylcellulose on hydroxypropyl-β-cyclodextrin complexation of hydrocortisone and its permeability through hairless mouse skin, Eur. J. Pharm. Sci. 2 (1994) 297-301.
28. T. Loftsson, H. Friôriksdóttir, S. Thórisdóttir, E. Stefánsson, The effect of hydroxypropyl methylcellulose on the release of dexamethasone from aqueous 2-hydroxypropyl-β-cyclodextrin formulations, Int. J. Pharm. 104 (1994) 181-184.
29. M. Umemura, H. Ueda, K. Tomono, T. Nagai, Effect of diethyl-β-cyclodextrin on the release of nitroglycerin from formulations, Drug Des. Deliv. 6 (1990) 297-310.
30. K. Tomono, H. Gotoh, M. Okamura, M. Horioka, H. Ueda, T. Nagai, Effect of β-cyclodextrins on sustained release of nitorglycerin from ointment bases, Yakuzaigaku 51 (1991) 22-28.
31. K. Kawahara, H. Ueda, K. Tomono, T. Nagai, Effect of diethyl β-cyclodextrin on the release and absorption behaviour of indomethacin from ointment bases, STP Pharm. Sci. 2 (1992) 506-513.
32. J. Szeman, H. Ueda, J. Szejtli, E. Fenyvesi, Y. Machida, T. Nagai, Complexation of several drugs with water-soluble cyclodextrin polymer, Chem. Pharm. Bull. 35 (1987) 282-288.
33. J. Szeman, H. Ueda, J. Szejtli, et al., Enhanced percutaneous absorption of homogenized tolnaftate/β-cyclodextrin polymer ground mixture, Drug Des. Deliv. 1 (1987) 325-332.
34. J.Y. Legendre, I. Rault, W. Luijten, I. Demuynck, S. Horvath, Effects of β-cyclodextrins on skin: Implications for the transdermal delivery of piribedil and a novel cognition enhancing-drug, S-9977, Eur. J. Pharm. Sci. 3 (1995) 311-322.
35. H. Okamoto, H. Komatsu, M. Hashida, H. Sezaki, Effects of β-cyclodextrin and di-O-methyl-β-cyclodextrin on the percutaneous absorption of butylparaben, indomethacin and sulfanilic acid, Int. J. Pharm. 30 (1986) 35-45.
36. T. Loftsson, N. Bodor, Effects of 2-hydroxypropyl-β-cyclodextrin on the aqueous solubility of drugs and transdermal delivery of 17β-estradiol, Acta Pharm. Nord. 1 (1989) 185-194.
37. M. Vitória, L.B. Bentley, R.F. Vianna, S. Wilson, J. Collett, Characterization of the influence of some cyclodextrins on the stratum corneum from the hairless mouse, J. Pharm. Pharmacol. 49 (1997) 397-402.
38. T. Loftsson, A.M. Sigurôardóttir, J.H. Olafsson, Improved acitretin delivery through hairless mouse skin by cyclodextrin complexation, Int. J. Pharm. 115 (1995) 255-258.
39. 1 on laurate-induced peripheral vascular occlusive sequelae in rabbits: optimized topical formulation with β-cyclodextrin derivative and penetration enhancer HPE-101, J. Pharm. Pharmacol. 44 (1992) 1033-1035.
40. S.D. Roy, G.J. De, Percutaneous absorption of nafarelin acetate, an LHRH analog, through human cadaver skin and monkey skin, Int. J. Pharm. 110 (1994) 137-145.
41. T. Ogiso, T. Paku, M. Iwaki, T. Tanino, S. Nishioka, Percutaneous absorption of physiologically active peptides, ebiratide and elcatonin, in rats, Biol. Pharm. Bull. 17 (1994) 1094-1100.
42. T. Ohshima, H. Yoshikawa, K. Takada, S. Muranishi, Enhancing effect of absorption promoters on percutaneous absorption of a model dye (6-carboxyfluorescein) as poorly absorbable drugs. II. Study on the absorption promoting effect of azone, J. Pharmacobio-Dyn. 8 (1985) 900-905.
43. U. Vollmer, B. Müller, B. Wilffert, T. Peters, An improved model for studies on transdermal drug absorption in-vivo in rats, J. Pharm. Pharmacol. 45 (1993) 242-245.
44. M. Tanaka, Y. Iwata, Y. Kouzuki, et al., Effect of 2-hydroxypropyl-β-cyclodextrin on percutaneous absorption of methyl paraben, J. Pharm. Pharmacol. 47 (1995) 897-900.
45. 14C-methyl-β-cyclodextrin in rats, Kluwer Academic Pub., Dordrecht, 1988, pp. 415-420.
46. T. Hoshino, K. Ishida, T. Irie, K. Uekama, T. Ono, Alleviation of chlorpromazine-photosensitized contact dermatitis by β-cyclodextrin derivatives and their possible mechanisms, J. Pharmacobio-Dyn. 12 (1989) s-70.
47. D. Amdidouche, P. Montassier, M.C. Poelman, D. Duchêne, Evaluation by laser Doppler velocimetry of the attenuation of tretinoin induced skin irritation by β-cyclodextrin complexation, Int. J. Pharm. 111 (1994) 111-116.
48. B.S. Kuchekar, J.R. Vakil, Characterisation of menadione-β-cyclodextrin inclusion complex, Indian Drugs 31 (1994) 282-283.
49. K. Uekama, T. Irie, M. Sunada, M. Otagiri, Y. Arimatsu, S. Nomura, Alleviation of prochlorperazine-induced primary irritation of skin by cyclodextrin complexation, Chem. Pharm. Bull. 30 (1982) 3860-3862.
50. D. Duchêne, D. Wouessidjewe, M.-C. Poelman, In New Trends in Cyclodextrin and Derivatives, In: D. Duchêne (Eds.), Editions de Santé, Paris, 1991, pp. 447-481.
51. E. Albers, B.W. Müller, Cyclodextrin derivatives in pharmaceutics, CRC Crit. Rev. Ther. Drug Carrier Syst. 12 (1995) 311-337.
52. P.G. van der Valk, M.C. Crijns, J.P. Nater, E. Bleumink, Skin irritancy of commercially available soap and detergent bars as measured by water vapour loss, Derm. Beruf. Umwelt. 32 (1984) 87-90.
53. A. Garnett, S.A. Hotchkiss, J. Caldwell, Percutaneous absorption of benzyl acetate through rat skin in-vitro. 3. A comparison with human skin, Food Chem. Toxicol. 32 (1994) 1061-1065.
54. M. Tanaka, H. Matsuda, H. Sumiyoshi, et al., 2-Hydroxypropylated cyclodextrins as a sustained-release carrier for fragrance materials, Chem. Pharm. Bull. 44 (1996) 416-420.
55. S.J. Lehner, B.W. Müller, J.K. Seydel, Interactions between p-hydroxybenzoic acid esters and hydroxypropyl-β-cyclodextrin and thier antimicrobial effect against Candida albicans, Int. J. Pharm. 93 (1993) 201-208.
56. J. Szejtli, Medicinal applications of cyclodextrins, Med. Res. Rev. 14 (1994) 353-386.
57. T. Takahashi, I. Kagami, K. Kitamura, Y. Nakanishi, Y. Imasato, Stabilization of AD-1590, a non-steroidal antiinflammatory agent, in suppository bases by β-cyclodextrin complexation, Chem. Pharm. Bull. 34 (1986) 1770-1774.
58. M. Kikuchi, F. Hirayama, K. Uekama, Improvement of oral and rectal bioavailabilities of carmofur by methylated β-cyclodextrin complexations, Int. J. Pharm. 38 (1987) 191-198.
59. H. Arima, T. Kondo, T. Irie, K. Uekama, Enhanced rectal absorption and reduced local irritation of the anti-inflammatory drug ethyl 4-biphenylylacetate in rats by complexation with water-soluble β-cyclodextrin derivatives and formulation as oleaginous suppository, J. Pharm. Sci. 81 (1992) 1119-1125.
60. T. Kondo, T. Irie, K. Uekama, Combination effects of α-cyclodextrin and xanthan gum on rectal absorption and metabolism of morphine from hollow-type suppositories in rabbits, Biol. Pharm. Bull. 19 (1996) 280-286.
61. N. Celebi, M. Iscanoglu, T. Degim, The release of naproxen in fatty suppository bases by β-cyclodextrin complexation, Pharmazie 46 (1991) 863-865.
62. R. Iwaoku, K. Arimori, M. Nakano, K. Uekama, Enhanced absorption of phenobarbital from suppositories containing phenobarbital-β-cyclodextrin inclusion complex, Chem. Pharm. Bull. 30 (1982) 1416-1421.
63. M. Otagiri, T. Imai, M. Matsuo, K. Uekama, Improvements to some pharmaceutical properties of flurbiprofen by β- and γ-cyclodextrin complexations, Acta Pharm. Suec. 20 (1983) 1-10.
64. K. Uekama, T. Imai, T. Maeda, T. Irie, F. Hirayama, M. Otagiri, Improvement of dissolution and suppository release characteristics of flurbiprofen by inclusion complexation with heptakis(2,6-di-O-methyl)-β-cyclodextrin, J. Pharm. Sci. 74 (1985) 841-845.
65. K. Uekama, T. Maeda, H. Arima, T. Irie, F. Hirayama, Possible utility of β-cyclodextrin in the preparation of biphenyllactic acid suppository, Yakugaku Zasshi 106 (1986) 1126-1130.
66. H.W. Frijlink, A.J.M. Schoonen, C.F Lerk, In: H. W. Frijlink (Eds.), The cyclodextrins on drug release from fatty suppository bases. In-vitro observations, Drukkerij van denderen B.V., Groningen, 1980, pp. 77-88.
67. H.W. Frijlink, S. Paiotti, A.C. Eissens, C.F. Lerk, The effects of cyclodextrins on drug release from fatty suppository bases. III. Application of cyclodextrin derivatives, Eur. J. Pharm. Biopharm. 38 (1992) 174-179.
68. H. Arima, T. Irie, K. Uekama, Differences in the enhancing effects of water soluble β-cyclodextrins on the release of ethyl 4-biphenylyl acetate, an anti-inflammatory agent from an oleaginous suppository base, Int. J. Pharm. 57 (1989) 107-115.
69. H.W. Frijlink, A.C. Eissens, A. Schoonen, C.F. Lerk, The effects of cyclodextrins on drug release from fatty suppository bases. II. In-vivo observations, Eur. J. Pharm. Biopharm. 37 (1991) 183-187.
70. S. Muranishi, Characteristics of drug absorption via the rectal route, Methods Find Exp. Clin. Pharmacol. 6 (1984) 763-772.
71. S. Muranishi, Absorption enhancers, CRC Crit. Rev. Ther. Drug Carrier Syst. 7 (1990) 1-33.
72. L. Hovgaard, H. Brondsted, Drug delivery studies in Caco2 monolayers. IV. Absorption enhancer effects of cyclodextrins, Pharm. Res. 12 (1995) 1328-1332.
73. Y. Watanabe, Y. Matsumoto, M. Seki, M. Takase, M. Matsumoto, Absorption enhancement of polypeptide drugs by cyclodextrins. I. Enhanced rectal absorption of insulin from hollow-type suppositories containing insulin and cyclodextrins in rabbits, Chem. Pharm. Bull. 40 (1992) 3042-3047.
74. Y. Watanabe, M. Kiriyama, R. Ito, et al., Pharmacodynamics and pharmacokinetics of recombinant human granulocyte colony-stimulating factor (rhG-CSF) after administration of a rectal dosage vehicle, Biol. Pharm. Bull. 19 (1996) 1059-1063.
75. K. Nakanishi, T. Nadai, M. Masada, K. Miyajima, Effect of cyclodextrins on biological membrane. I. Effect of cyclodextrins on the absorption of a non-absorbable drug from rat small intestine and rectum, Chem. Pharm. Bull. 38 (1990) 1684-1687.
76. H. Yanagi, N. Ishikura, H. Kenmotsu, et al., Effect of inclusion complexation of decanoic acid with α-cyclodextrin on rectal absorption of cefmetazole sodium suppository in rabbits, Yakugaku Zasshi 111 (1991) 65-69.
77. Y. Kaji, K. Uekama, H. Yoshikawa, K. Takada, S. Muranishi, Selective transfer of 1-hexylcarbamoyl-5-fluorouracil into lymphatics by combination of β-cyclodextrin polymer complexation and absorption promotor in the rat, Int. J. Pharm. 24 (1985) 79-89.
78. K. Uekama, T. Kondo, K. Nakamura, et al., Modification of rectal absorption of morphine from hollow-type suppositories with a combination of α-cyclodextrin and viscosity-enhancing polysaccharide, J. Pharm. Sci. 84 (1995) 15-20.
79. S.Y. Lin, J.C. Yang, Effect of β-cyclodextrin on the in-vitro permeation rate and in-vivo rectal absorption of acetaminophen hydrogel preparations, Pharm. Acta Helv. 65 (1990) 262-268.
80. H. Arima, T. Kondo, T. Irie, et al., Use of water-soluble β-cyclodextrin derivatives as carriers of anti-inflammatory drug biphenylylacetic acid in rectal delivery, Yakugaku Zasshi 112 (1992) 65-72.
81. S. Costa, G. Zinelli, L. Bufalino, Piroxicam-β-cyclodextrin in the treatment of dysmenorrhoea, Drug Invest. 4 (1990) 73-78.